Dr. Steven M. Albelda, Director of Lung Research, Co-Director of Thoracic Oncology Laboratories

Steven M. Albelda

Director of Lung Research, Co-Director of Thoracic Oncology Laboratories

Since graduating from medical school in 1979, Steven M. Albelda, M.D., has become a notable clinician and researcher in the field of mesothelioma.

Get in touch

Content Contributors

Scroll

Written By

This page features: 11 cited research articles

About Steven M. Albelda

Accolades
  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Mesothelioma Pioneer icon

    Mesothelioma Pioneer

  • Team Leader icon

    Team Leader

  • 30+ Years of Experience icon

    30+ Years of Experience

  • Immunotherapy icon

    Immunotherapy

His influence can be seen throughout the world of mesothelioma research. His varied efforts have led to developing novel approaches to the treatment of lung and other cancers of the chest wall.

Albelda’s multidisciplinary Thoracic Oncology Research Laboratory (TORL) pioneered the use of immunogene therapy to treat a variety of cancers. The lab conducted the first trials of gene therapy in mesothelioma patients.

Research and Studies

He is associate editor of the American Journal of Respiratory Cell and Molecular Biology, holds positions on the editorial boards of Cancer Gene Therapy and the American Journal of Physiology, and has published more than 140 articles in numerous journals, all peer-reviewed.

Now at the University of Pennsylvania’s School of Medicine, Albelda is the director of Lung Research, co-director of TORL, vice chief of the Pulmonary, Allergy and Critical Care Division and a professor of medicine.

His research involves work with human tumor samples, animal models and the conduct of clinical trials. At the Monell Chemical Senses Center in Pennsylvania, Albelda took part in a clinical trial seeking to detect early signs of lung cancer tumors by screening at-risk patients like smokers.

Focus on Mesothelioma Treatments

Albelda in 2007 spoke about newer approaches to mesothelioma treatment at the annual meeting of the National Research Centre for Asbestos Related Diseases in Australia.

At the conference, Albelda said:

Dr. Albelda Director of Lung Research, Co-Director of Thoracic Oncology Laboratories

“Existing treatments for mesothelioma really only do half the job in tackling the disease, so researchers across the globe are looking for ways to increase a patient’s quality and length of life after diagnosis. An area that holds much promise, we believe, is combining tumor surgery or chemotherapy with treatments, such as vaccines, that can boost the body’s own immune system response and help us stop mesothelioma in its tracks.”

He also has participated in research that examines using a patient’s own immune system to fight mesothelioma cancer. He described the process in the American Journal of Respiratory Cell and Molecular Biology.

“Now you’re just using the gene therapy to trigger the immune system, and most of the killing [of cancer cells] will be done by the body’s own immune system,” Albelda said.

Albelda took part in clinical trials alongside Dr. Daniel Sterman of the Abramson Cancer Center in Pennsylvania, measuring the outcomes of genetically altered T-cells used to target mesothelioma tumors.

Talk to a Doctor About Your Diagnosis

We can help you or a loved one get in contact with Dr. Albelda and find the treatment that's best for you.

Get Started Today

In a trial sponsored by the National Cancer Institute and the Richard M. Schulze Family Foundation, Albelda spent time evaluating the effects of using the common cold virus for mesothelioma tumor regression. He hopes they will eventually use interferon-alpha, an immune system stimulant, to fight early stage malignant mesothelioma.

The Wagner Award

In 2010, Albelda received the Wagner Award, the highest honor presented by the International Mesothelioma Interest Group.

The recognition is given every two years to a leader in the field who has made the most major and original contribution to the understanding of mesothelioma.

“Dr. Albelda is one of the rare individuals who have made outstanding contributions in both the basic biology of mesothelioma and in clinical application of this knowledge to patients,” his award letter showed. “His work is poised to make significant therapeutic advances for this intractable malignancy.”

See More Top Mesothelioma Doctors

Publications

Albeda’s writing primarily focuses on genetic therapy and growth factor for solid cancers. His work has appeared in Clinical Cancer Research and Critical Care Medicine, among other journals.

Disclaimer: Dr. Steven M. Albelda has no professional affiliation with Asbestos.com.

Steven M. Albelda
Get Help Contacting Steven M. Albelda

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

Get the Best Treatment Options

Find a Doctor
Asbestos.com Mesothelioma Packet

Order Your Free Treatment Guide

Get Yours Now

Find a Mesothelioma Clinical Trial Near You

Get Help Now

Share this article

Last Modified October 17, 2018

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

4 Cited Article Sources

  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

On This Page

Content Contributors

Share Our Page

Free Awareness Wristbands

Get free mesothelioma wristbands to show support for a loved one

Get your wristbands Mesothelioma Wristbands
Get Your Free Mesothelioma Guide Chat live with a patient advocate now loading spinner